Fever

An Exciting New Biomarker for Detecting Inflammation in Dogs - VMRD SAA for Canine Now Available!

Retrieved on: 
Wednesday, January 31, 2024

PULLMAN, Va., Jan. 31, 2024 /PRNewswire-PRWeb/ -- Veterinary diagnostics manufacturer VMRD, Inc is delighted to announce the expansion of their patient-side product line to include serum amyloid A (SAA) tests for dogs! The addition of VMRD SAA for Canine to the existing SAA products for Feline and Equine offers even greater opportunity for veterinarians to elevate their patient care with improved detection of inflammation and infection in more species.

Key Points: 
  • This new offering, VMRD SAA for Canine, complements existing SAA products for Feline and Equine, providing veterinarians with enhanced capabilities for detecting inflammation and infection in a broader range of species, offering rapid and sensitive results within 10 minutes.
  • The addition of VMRD SAA for Canine to the existing SAA products for Feline and Equine offers even greater opportunity for veterinarians to elevate their patient care with improved detection of inflammation and infection in more species.
  • "The availability of VMRD SAA for Canine and VMRD SAA for Feline is a big win for companion animal veterinarians and their patients," declares Dr. Hines.
  • For more information on VMRD point-of-care products, including the VMRD SAA test for Canine, please visit our website at vmrd.com/poc or contact us at [email protected] .

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

Porsche 963 of Porsche Penske Motorsport victorious after gripping 24 Hours of Daytona

Retrieved on: 
Monday, January 29, 2024

7 Porsche 963 fielded by the Porsche Penske Motorsport factory team has won the 24 Hours of Daytona.

Key Points: 
  • 7 Porsche 963 fielded by the Porsche Penske Motorsport factory team has won the 24 Hours of Daytona.
  • “The entire Porsche Penske Motorsport works team and everyone at the development center in Weissach [Germany] have worked extremely hard to lay the foundations for this success.
  • Four Porsche 963, two from Porsche Penske Motorsport and two from our strong customer teams, made it through without any major technical problems – that’s quite a feat in itself.
  • Daytona was definitely worth the trip for us.”
    “An amazing day for the entire Porsche Penske Motorsport organization,” said Roger Penske, Founder and Chairman of the Penske Corporation.

FSIS Public Health Alert 01182024-02 - POSSIBLE SALMONELLA CONTAMINATION

Retrieved on: 
Friday, January 19, 2024

Label images can be found in the Centers for Disease Control and Prevention (CDC) Food Safety Alert .

Key Points: 
  • Label images can be found in the Centers for Disease Control and Prevention (CDC) Food Safety Alert .
  • FSIS has been working with the CDC and state public health partners to investigate a multistate outbreak of 47 Salmonella I 4:i:- illnesses in 22 states with onset dates ranging from November 20, 2023, through January 1, 2024.
  • Media with questions regarding the public health alert can contact Marco Lastrico, Public Relations, Busseto Foods, at 917-634-1685 or [email protected] .
  • Consumers with questions regarding the public health alert can contact the Busseto Recall Hotline at 866-552-4916.

MedStar Health Warns: Contagious and Symptomatic Ravens Fever on the Rise

Retrieved on: 
Friday, January 26, 2024

BALTIMORE, Jan. 26, 2024 /PRNewswire/ -- In advance of Sunday's AFC title game at M&T Bank Stadium, MedStar Health, the largest healthcare system in the Maryland-D.C. region, warns that a highly contagious and symptomatic fever is raging coast to coast. Known as Ravens Fever, experts predict the number of those afflicted is likely to explode exponentially over the next two weeks.

Key Points: 
  • BALTIMORE, Jan. 26, 2024 /PRNewswire/ -- In advance of Sunday's AFC title game at M&T Bank Stadium, MedStar Health , the largest healthcare system in the Maryland-D.C. region, warns that a highly contagious and symptomatic fever is raging coast to coast.
  • Known as Ravens Fever , experts predict the number of those afflicted is likely to explode exponentially over the next two weeks.
  • Ravens Fever has even reached the mother and baby units at MedStar Franklin Square Medical Center and MedStar Harbor Hospital, where newborn fans are all wearing purple Ravens-branded onesies.
  • Symptoms of Ravens Fever may include:
    Anyone experiencing Ravens Fever symptoms can let others know on Instagram, using the Ravens Fever filter.

Optimism Takes Center Stage at CES 2024

Retrieved on: 
Thursday, January 25, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The Consumer Electronics Show (CES) is among the most influential technology events in the world—the proving ground for breakthrough technologies and global innovators. Analysts from global technology intelligence firm ABI Research were there in Las Vegas, on the show floor and in meeting rooms around the event, to take the pulse of where the industry is going and what technology leaders, implementers, and innovators are thinking, prioritizing, and investing in right now. Their insights have been compiled in ABI Research's Key Takeaways From CES 2024 whitepaper.

Key Points: 
  • Their insights have been compiled in ABI Research's Key Takeaways From CES 2024 whitepaper.
  • "Of all the products, ideas, and concepts on display at CES 2024, the most surprising—and perhaps important—was confidence.
  • Despite a year of doom and gloom fueled by inflation, confounding monetary policy, wars, and political tumult, there was a definite and palpable buzz of positivity in the air at CES 2024.
  • The Key Takeaways From CES 2024 whitepaper provides reporting on the following technologies:

Optimism Takes Center Stage at CES 2024

Retrieved on: 
Thursday, January 25, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The Consumer Electronics Show (CES) is among the most influential technology events in the world—the proving ground for breakthrough technologies and global innovators. Analysts from global technology intelligence firm ABI Research were there in Las Vegas, on the show floor and in meeting rooms around the event, to take the pulse of where the industry is going and what technology leaders, implementers, and innovators are thinking, prioritizing, and investing in right now. Their insights have been compiled in ABI Research's Key Takeaways From CES 2024 whitepaper.

Key Points: 
  • Their insights have been compiled in ABI Research's Key Takeaways From CES 2024 whitepaper.
  • "Of all the products, ideas, and concepts on display at CES 2024, the most surprising—and perhaps important—was confidence.
  • Despite a year of doom and gloom fueled by inflation, confounding monetary policy, wars, and political tumult, there was a definite and palpable buzz of positivity in the air at CES 2024.
  • The Key Takeaways From CES 2024 whitepaper provides reporting on the following technologies:

Blue Spark Technologies Launches Innovative Multi-Vital Remote Patient Monitoring Platform - VitalTraq™

Retrieved on: 
Thursday, January 25, 2024

CLEVELAND, Jan. 25, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc., a global leader in clinical-grade wearable and digital health tech, is launching a first-of-its-kind multi-sensor remote patient monitoring platform, VitalTraq™. VitalTraq includes one of the most groundbreaking contactless vital sign measurement sensors to date, Remote Photoplethysmography (rPPG). Using a simple 30 to 60-second selfie scan, patients, clinicians, and researchers can collect digital measurements, including Heart Rate, Heart Rate Variability, Blood Pressure, and Respiratory Rate vital signs in a single contactless patient experience. 

Key Points: 
  • CLEVELAND, Jan. 25, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc ., a global leader in clinical-grade wearable and digital health tech, is launching a first-of-its-kind multi-sensor remote patient monitoring platform, VitalTraq™ .
  • Using groundbreaking, clinically validated Remote Photoplethysmography technology, patients scan their faces for a reading that captures blood flow patterns and translates them into vital sign measurements in a single remote monitoring platform.
  • "The VitalTraq platform is ideally suited to remote patient monitoring in clinical trials as well as applications such as post-surgical patient monitoring for complications such as sepsis," said John Gannon, President and CEO of Blue Spark Technologies.
  • The VitalTraq remote patient monitoring platform consists of iOS and Android mobile patient applications, the HIPAA-compliant VitalTraq Connect cloud service hosted on the Google Cloud Platform, and a web-based clinical remote monitoring dashboard.

House Calls in 2024: Mercy Patients Get Hospital Care at Home

Retrieved on: 
Thursday, January 18, 2024

Cue Dr. Aaron Pickrell, Mercy hospitalist and regional medical director of Mercy Hospital-at-Home, who approached Alexander with a new program.

Key Points: 
  • Cue Dr. Aaron Pickrell, Mercy hospitalist and regional medical director of Mercy Hospital-at-Home, who approached Alexander with a new program.
  • "He said they would send me home in an ambulance and care for me like I was in the hospital.
  • Just like Alexander, Marty Kiefer's most recent visit to Mercy Hospital St. Louis ended with a move into his home.
  • Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies.

Public advisory - Pediatrix Acetaminophen Oral Solution for children: One lot recalled due to potential risk of overdose

Retrieved on: 
Wednesday, January 17, 2024

Children may be especially at risk of the effects of acetaminophen overdose given their small size and developing bodies.

Key Points: 
  • Children may be especially at risk of the effects of acetaminophen overdose given their small size and developing bodies.
  • Signs of acetaminophen overdose include nausea, vomiting, lethargy, sweating, loss of appetite and pain in the upper part of the abdomen or stomach.
  • Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours.
  • Given the limited scope of the recall, it will not have any impact on the general availability of children's acetaminophen products.